GEN Exclusives

More »

GEN News Highlights

More »
May 26, 2009

NanoViricides Taps Thevac for Preclinical Studies on Flu Drug

  • NanoViricides  signed a preclinical study agreement for the evaluation of FluCide™, its universal anti-influenza drug candidate. Thevac, a spin-off of the Louisiana State University, will conduct the study.

    Initially, the research will evaluate effectiveness of nanoviricide™ drug candidates against a virulent H1N1 strain that caused a severe outbreak in 1930. This well-characterized virus is expected to be a good surrogate for the current swine flu. The study will then be expanded to include other influenza subtypes that are feared to be on the horizon, such as H3N2.

    FluCide is currently in IND-enabling studies in bird flu. NanoViricides believes that it is possible to design a single drug capable of attacking most influenza viruses, because they all use the same cell-surface receptor, sialic acid.

     


    ♦♦♦
    Past News from NanoViricides
    Nanoviricides and Walter Reed Team Up to Fight Dengue Fever (Apr. 9, 2007)



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?